Phenotypic transformation not only reflects the remarkable plasticity and adaptive capacity of tumor cells under therapeutic pressure but also highlights the limitations of ALK-targeted monotherapy, supporting the rationale for the development of combination strategies incorporating phenotype-reversing agents or other adjunctive therapeutic modalities. The gene discussed is ALK; the disease is neoplasm.